

## SNT-4728 pre-readout informational webinar

**Syntara Limited (ASX: SNT)**, a clinical-stage drug development company, is pleased to announce an investor webinar at **12pm AEST on Monday 1 June 2026** to provide further information regarding the ongoing Phase 2 trial of SNT-4728, ahead of the topline data readout expected by the end of June.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_o9oknkkHSlew9S8zwKpj\\_g](https://us02web.zoom.us/webinar/register/WN_o9oknkkHSlew9S8zwKpj_g)

As part of the webinar, Syntara's CEO Gary Phillips and Head of Drug Discovery Dr Wolfgang Jarolimek will be joined by special guests:

- Dr Lynsey Bilsland – Managing Director of Parkinson's Research Venture

Dr Bilsland is Managing Director of Parkinson's Research Ventures, which invests in the development of new therapies for people living with Parkinson's. Prior to joining Parkinson's UK in July 2025, Lynsey spent 16 years at Wellcome, investing in mission-driven healthcare solutions and driving their successful translation towards tangible healthcare impact. Latterly as Wellcome's Head of Mental Health Innovation, Lynsey was responsible for sourcing and developing a diverse portfolio of interventions and tools to support people with anxiety, depression and psychosis. Lynsey has a PhD in Neuroscience from University College London and a Bachelor of Science (Honours) in Pharmacology from the University of Glasgow.

- Professor Simon Lewis – Neurologist & Trial Principal Investigator

Professor Simon Lewis is a Consultant Neurologist and Professor of Cognitive Neuroscience at the The University of Sydney, with internationally recognised expertise in Parkinson's disease and related neurodegenerative disorders. He is Clinical Director of the Ageing Brain Clinic and Director of the Parkinson's Disease Research Clinic at the Brain and Mind Centre, and also leads the NSW Movement Disorders Brain Donor Program. Prof Lewis has published more than 250 peer-reviewed papers, authored two books and secured over A\$10 million in competitive research funding, including

from the NHMRC, ARC and Michael J. Fox Foundation. His research focuses on improving quality of life and advancing therapeutic approaches for people living with neurodegenerative disease.

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that wish to join by phone.

Questions can be submitted live during the webinar or sent in advance to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Please note a replay of the webinar will be available at the above-mentioned link shortly following the conclusion of the live session.

### About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome have been initiated.

Syntara is also advancing topical pan-LOX inhibitors with SNT-9465 in a Phase 1a/b study of hypertrophic scars and continuing the ongoing collaboration with Professor Fiona Wood and the University of Western Australia studying SNT-6302 in keloid scars. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. [www.syntaraTX.com.au](http://www.syntaraTX.com.au).

#### SOURCE:

Syntara Limited (ASX: SNT),  
Sydney, Australia  
(ABN: 75 082 811 630)

#### AUTHORISED FOR RELEASE TO ASX BY:

Syntara Limited Disclosure Committee.

#### CONTACT:

##### Syntara investor / media relations:

Matthew Wright  
NWR Communications  
+61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

[JOIN THE SYNTARA MAILING LIST HERE](#)



For personal use only